Published in Cancer Res on March 17, 2009
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell (2012) 1.95
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res (2011) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol (2013) 1.29
Regulatory dendritic cells: there is more than just immune activation. Front Immunol (2012) 1.25
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 1.17
Tumor associated regulatory dendritic cells. Semin Cancer Biol (2012) 1.08
Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J Immunol (2010) 1.05
Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest (2012) 1.05
Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One (2012) 1.00
Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest (2012) 1.00
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol (2011) 0.99
The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res (2011) 0.99
Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth. J Immunol (2012) 0.97
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. PLoS One (2011) 0.96
Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming. PLoS One (2012) 0.96
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.95
Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol (2014) 0.95
Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation. Eur J Immunol (2013) 0.95
Influence of synthetic superparamagnetic iron oxide on dendritic cells. Int J Nanomedicine (2011) 0.94
Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett (2010) 0.92
Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J (2013) 0.90
Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients. Clin Exp Med (2011) 0.90
Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells. Cancer Immunol Res (2016) 0.90
Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother (2013) 0.89
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
In vivo migration of dendritic cells labeled with synthetic superparamagnetic iron oxide. Int J Nanomedicine (2011) 0.88
Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One (2011) 0.88
Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat Rev Urol (2009) 0.88
Mechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responses. PLoS One (2012) 0.87
Immune heterogeneity in neuroinflammation: dendritic cells in the brain. J Neuroimmune Pharmacol (2012) 0.86
Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol (2012) 0.84
Effector CD8+ T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia. Int J Hyperthermia (2012) 0.84
The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells. Oncogene (2015) 0.83
Immunoregulation therapy changes the frequency of interleukin (IL)-22+ CD4+ T cells in systemic lupus erythematosus patients. Clin Exp Immunol (2014) 0.83
Tolerogenic pDCs: spotlight on Foxo3. J Clin Invest (2011) 0.82
Obesity triggers enhanced MDSC accumulation in murine renal tumors via elevated local production of CCL2. PLoS One (2015) 0.82
Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron (2013) 0.81
Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models. Oncoimmunology (2012) 0.80
Immune regulation of bone metastasis. Bonekey Rep (2014) 0.80
Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica (Cairo) (2012) 0.80
Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer (2014) 0.80
Fluorescent-tilmanocept for tumor margin analysis in the mouse model. J Surg Res (2014) 0.80
Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines (2014) 0.79
Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. Front Immunol (2013) 0.78
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion. PLoS One (2013) 0.78
The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. Oncoimmunology (2016) 0.78
Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease. Mol Cell Pediatr (2016) 0.77
T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1. Biomed Res Int (2015) 0.77
Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. Trends Cancer (2016) 0.77
The migration of synthetic magnetic nanoparticle labeled dendritic cells into lymph nodes with optical imaging. Int J Nanomedicine (2013) 0.77
T cells encountering myeloid cells programmed for amino acid-dependent immunosuppression use Rictor/mTORC2 for proliferative checkpoint decisions. J Biol Chem (2016) 0.76
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. Oncotarget (2016) 0.76
Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissue. PLoS One (2013) 0.76
Retinoic acid on stage in antitumor immunity. Oncoimmunology (2013) 0.75
State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther (2016) 0.75
Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. Front Immunol (2017) 0.75
Leukocyte populations and IL-6 in the tumor microenvironment of an orthotopic colorectal cancer model. Acta Biochim Biophys Sin (Shanghai) (2016) 0.75
Obesity alters immune and metabolic profiles: New insight from obese-resistant mice on high-fat diet. Obesity (Silver Spring) (2016) 0.75
Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010. J Immunother (2010) 0.75
Cancer: A dendritic-cell brake on antitumour immunity. Nature (2015) 0.75
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Dendritic cells in a mature age. Nat Rev Immunol (2006) 5.03
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
DC-based cancer vaccines. J Clin Invest (2007) 3.81
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity (2007) 3.58
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 3.47
Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity (2003) 3.28
Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol (2004) 3.25
L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2006) 3.17
Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res (1998) 3.00
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 2.54
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med (2007) 2.25
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity (2003) 1.97
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Stromal cells direct local differentiation of regulatory dendritic cells. Immunity (2004) 1.58
Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci U S A (2005) 1.37
A feedback transcriptional mechanism controls the level of the arginine/lysine transporter cat-1 during amino acid starvation. Biochem J (2007) 1.32
Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol (2004) 1.29
Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res (2003) 1.24
Amino acid regulation of gene expression. J Nutr (2001) 1.14
Priming in the presence of IL-10 results in direct enhancement of CD8+ T cell primary responses and inhibition of secondary responses. J Immunol (2005) 1.03
No intrinsic deficiencies in CD8+ T cell-mediated antitumor immunity with aging. J Immunol (2004) 1.01
Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. Int J Cancer (2004) 1.00
Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol (2003) 0.88
Rapid maturation of effector T cells in tumors, but not lymphoid organs, during tumor regression. PLoS One (2007) 0.79
T cell-mediated delay of spontaneous mammary tumor onset: increased efficacy with in vivo versus in vitro activation. J Immunol (2005) 0.79
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
The immunological synapse balances T cell receptor signaling and degradation. Science (2003) 4.94
Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol (2006) 4.87
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
T cell receptor signaling precedes immunological synapse formation. Science (2002) 4.56
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66
Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. Immunity (2013) 3.51
Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe (2011) 3.46
Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol (2004) 3.25
L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2006) 3.17
Cutting edge: TREM-2 attenuates macrophage activation. J Immunol (2006) 3.07
AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol (2011) 2.99
NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol (2002) 2.92
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol (2007) 2.61
Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med (2006) 2.55
An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med (2008) 2.50
Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo. J Exp Med (2002) 2.47
Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol (2004) 2.44
HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A (2008) 2.31
The balance between T cell receptor signaling and degradation at the center of the immunological synapse is determined by antigen quality. Immunity (2008) 2.13
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood (2005) 1.94
Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nat Immunol (2002) 1.92
DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature (2008) 1.88
Specificity of T-cell alloreactivity. Nat Rev Immunol (2007) 1.88
Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol (2007) 1.88
How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nat Immunol (2012) 1.80
An endogenous peptide positively selects and augments the activation and survival of peripheral CD4+ T cells. Nat Immunol (2009) 1.78
Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med (2007) 1.76
Evidence for MR1 antigen presentation to mucosal-associated invariant T cells. J Biol Chem (2005) 1.72
Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.69
Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 1.68
Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol (2002) 1.68
Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med (2009) 1.67
Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol (2002) 1.67
Melanoma differentiation-associated gene 5 (MDA5) is involved in the innate immune response to Paramyxoviridae infection in vivo. PLoS Pathog (2010) 1.66
Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease. Sci Transl Med (2013) 1.63
Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur J Immunol (2005) 1.62
Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology (2013) 1.57
Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe (2012) 1.54
Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J Exp Med (2003) 1.54
Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis (2006) 1.53
Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol (2003) 1.53
The stimulatory potency of T cell antigens is influenced by the formation of the immunological synapse. Immunity (2007) 1.52
Plasmacytoid dendritic cells--virus experts of innate immunity. Semin Immunol (2005) 1.52
Immature CD4(+)CD8(+) thymocytes form a multifocal immunological synapse with sustained tyrosine phosphorylation. Immunity (2002) 1.50
Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem (2012) 1.50
Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J Immunol (2004) 1.48
Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest (2015) 1.46
Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci U S A (2005) 1.46
The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood (2005) 1.46
Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc Natl Acad Sci U S A (2005) 1.46
Pillars article: separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991. 252: 1308-1310. J Immunol (2011) 1.45
L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol (2005) 1.45
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
Binding of immunogenic peptides to Ia histocompatibility molecules. 1985. J Immunol (2005) 1.42
Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol (2005) 1.42
Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood (2005) 1.41
Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 1.41
OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest (2011) 1.38
Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain (2008) 1.38
Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). J Immunol (2004) 1.37
IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J Immunol (2002) 1.36
A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. Blood (2003) 1.35
p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity (2007) 1.30
TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol (2012) 1.30
Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J Immunol (2006) 1.30
Adhesive mechanisms governing interferon-producing cell recruitment into lymph nodes. J Exp Med (2005) 1.29
Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med (2005) 1.26
Identification of a novel inhibitory actin-capping protein binding motif in CD2-associated protein. J Biol Chem (2006) 1.23
Cutting edge: Salivary gland NK cells develop independently of Nfil3 in steady-state. J Immunol (2014) 1.22
Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol (2003) 1.22
Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node. Proc Natl Acad Sci U S A (2002) 1.21
Role for plastin in host defense distinguishes integrin signaling from cell adhesion and spreading. Immunity (2003) 1.21
Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells. J Exp Med (2004) 1.20
Phosphatidylinositol 3-kinase activation is required to form the NKG2D immunological synapse. Mol Cell Biol (2007) 1.18
Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J Exp Med (2006) 1.17
Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood (2010) 1.17